India Market Growth and Financial Performance
Other Markets: Key Highlights
Consistent performance in developed markets
EU
EU
Steady growth registered in
key markets
Growth driven by higher
LuforbecⓇ and tender sales
Brazil
•
South Africa
•
7th largest generics player¹
Revenues up 20% YoY and 9%
QoQ (local currency)
Mexico
Australia
4th largest generics player²
New launches from SCP
Philippines
portfolio
API + Global
Institutional
Note:
1. IQVIA MAT Dec 23 by sales
2. IQVIA Midas Sales Audit Dec-23
Emerging Markets
BRL 54 mn sales in Q3 FY24
Rank 2nd in reference market³
LUPIN
Revenues up 150% QoQ (local
currency)
Resumption of site during
quarter
21% YoY (local currency) growth
driven by renal and women's
health
Global Institutional business growth driven by higher Anti-TB sales
3. IQVIA MAT Dec-23 units
10View entire presentation